"The chip is the machine"... maybe you can't sell the machine.
-
-
I heard that ILMN just started offering up to the full trade-in value of the PGM toward the purchase of a MiSeq...
Comment
-
Got a source?Originally posted by SEQseekers View PostI heard that ILMN just started offering up to the full trade-in value of the PGM toward the purchase of a MiSeq...Comment
-
The number I heard was $26,000 off a MiSeq with a qualifying trade. Qualifying trade-ins included ABI 31xx, & 37xx machines, SOLiD, 454 GS-Flx and others. I can't remember specifically if the PGM was included, I wouldn't be surprised if it was, but the trade allowance was no where near full retail on the instrument.Originally posted by SEQseekers View PostI heard that ILMN just started offering up to the full trade-in value of the PGM toward the purchase of a MiSeq...Comment
-
I had overheard that it was $26K for the listed above and up to $49K for the PGM. Don't know if anyone has done it yet, but guess it could hurt to hit up the rep if your interested.Comment
-
Checking further I found the $26K was offered on:Originally posted by SEQseekers View Post
ABI 31xx, 37xx
ABI SOLiD
ILMN GA (I'm not sure if this means the GAII/GAIIx are excluded.)
Roche/454 GS-FLX & GSjr.
The PGM was not on the list.Comment
-
I just had a chance to speak an Illumina Rep and he did confirm that there is a PGM - MiSeq trade-in program going on right now for up to the full $50K - As we don't have a PGM (but just looking into desktop sequencing) he was not overly eager to go into details with me - So, I guess there are a few stipulation and he was not really clear about when the promotion ends... Hope this helpsComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment